After 4 months of therapy with secukinumab, a 67-year-old man with moderate psoriasis developed generalized hypertrichosis, along with PASI 90. The patient denied any drug intake, apart from secukinumab, nor applications of any creams. Moreover, this event did not really bother the patient, thus the therapy was not discontinued and the hypertrichosis is persisting as psoriasis' control.
Keywords: alopecia areata; anti-IL17; drug adverse events; hypertrichosis; psoriasis.
© 2019 Wiley Periodicals, Inc.